Compare GPRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | VYGR |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.6M | 193.5M |
| IPO Year | 2014 | 2015 |
| Metric | GPRO | VYGR |
|---|---|---|
| Price | $0.96 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.89 |
| AVG Volume (30 Days) | ★ 6.0M | 949.4K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $651,542,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.48 | $129.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $1.70 |
| 52 Week High | $2.05 | $5.19 |
| Indicator | GPRO | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 29.21 |
| Support Level | $0.94 | N/A |
| Resistance Level | $1.17 | $2.29 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 4.01 | 2.91 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.